nirsevimab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Not indicated for adults, see Pediatric Dosing & Uses

Respiratory Syncytial Virus Prevention

Pending FDA approval as a single SC injection to prevent respiratory syncytial virus (RSV) in infants, including those born healthy, at term or preterm, or with specific health conditions

Next:

Pharmacology

Mechanism of Action

Recombinant human IgG1 kappa monoclonal antibody that binds the F1 and F2 subunits of the RSV fusion (F) protein at a highly conserved epitope; this binding locks the RSV F protein in the prefusion conformation to block viral entry into the host cell

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.